Scleroderma pathophysiology: Difference between revisions

Jump to navigation Jump to search
Anthony Gallo (talk | contribs)
m Categories
Eiman (talk | contribs)
No edit summary
Line 7: Line 7:


==Pathophysiology==
==Pathophysiology==
The overproduction of collagen is thought to result from an [[autoimmune disorder|autoimmune dysfunction]], in which the immune system would start to attack the [[kinetochore]] of the chromosomes. This would lead to genetic malfunction of nearby genes. [[T cell]]s accumulate in the skin; these are thought to secrete [[cytokine]]s and other proteins that stimulate collagen deposition. Stimulation of the [[fibroblast]], in particular, seems to be crucial to the disease process, and studies have converged on the potential factors that produce this effect.<ref name="pmid14706971">{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=[[Annals of Internal Medicine]] |volume=140 |issue=1 |pages=37–50 |year=2004 |month=January |pmid=14706971 |doi= |url=http://www.annals.org/article.aspx?volume=140&page=37 |accessdate=2012-08-30}}</ref>
A significant player in the process is [[transforming growth factor]] (TGFβ). This protein appears to be overproduced, and the fibroblast (possibly in response to other stimuli) also overexpresses the receptor for this mediator. An intracellular pathway (consisting of ''SMAD2/SMAD3'', ''SMAD4'' and the inhibitor ''SMAD7'') is responsible for the secondary messenger system that induces [[transcription (genetics)|transcription]] of the proteins and enzymes responsible for collagen deposition. ''Sp1'' is a [[transcription factor]] most closely studied in this context. Apart from TGFβ, connective tissue growth factor (CTGF) has a possible role.<ref name="pmid14706971">{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=[[Annals of Internal Medicine]] |volume=140 |issue=1 |pages=37–50 |year=2004 |month=January |pmid=14706971 |doi= |url=http://www.annals.org/article.aspx?volume=140&page=37 |accessdate=2012-08-30}}</ref>
Damage to [[endothelium]] is an early abnormality in the development of scleroderma, and this too seems to be due to collagen accumulation by fibroblasts, although direct alterations by cytokines, [[platelet]] adhesion and a type II hypersensitivity reaction have similarly been implicated. Increased [[endothelin]] and decreased [[vasodilation]] has been documented.<ref name="pmid14706971">{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=[[Annals of Internal Medicine]] |volume=140 |issue=1 |pages=37–50 |year=2004 |month=January |pmid=14706971 |doi= |url=http://www.annals.org/article.aspx?volume=140&page=37 |accessdate=2012-08-30}}</ref>
Jimenez & Derk<ref name="pmid14706971">{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=[[Annals of Internal Medicine]] |volume=140 |issue=1 |pages=37–50 |year=2004 |month=January |pmid=14706971 |doi= |url=http://www.annals.org/article.aspx?volume=140&page=37 |accessdate=2012-08-30}}</ref> describe three theories about the development of scleroderma:
* The abnormalities are primarily due to a physical agent, and all other changes are secondary or reactive to this direct insult.
* The initial event is fetomaternal cell transfer causing microchimerism, with a second summative cause (e.g. environmental) leading to the actual development of the disease.
* Physical causes lead to phenotypic alterations in susceptible cells (e.g. due to genetic makeup), which then effectuate DNA changes which alter the cell's behavior.
===Gross Pathology===


====Cardiovascular====
====Cardiovascular====

Revision as of 01:18, 6 February 2018

Scleroderma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Scleroderma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Scleroderma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Scleroderma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Scleroderma pathophysiology

CDC on Scleroderma pathophysiology

Scleroderma pathophysiology in the news

Blogs on Scleroderma pathophysiology

Directions to Hospitals Treating Scleroderma

Risk calculators and risk factors for Scleroderma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Cardiovascular

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

References


Template:WikiDoc Sources